Despite impressions to the contrary, federal officials plan to pursue drug makers for illegal marketing, according to one Department of Justice official who recently provided a roadmap for those seeking to identify bad behavior.
At issue is off-label marketing, a contentious topic that has resulted in huge fines paid by numerous drug makers over the years and is now at the center of a free speech struggle between the pharmaceutical industry and the Food and Drug Administration.
About the Author Reprints
